Coagulation

Global Rare Hemophilia Factors Market Analysis Report 2023-2030 - Tailored Factor Concentrates Gain FDA Approval, Fueling Rare Hemophilia Factors Market Growth

Retrieved on: 
Tuesday, October 3, 2023
Orphan Drug Act of 1983, Fresh frozen plasma, Infection, Hand, Prevalence, Personal protective equipment, Health care, COVID-19, Quality of life, Haemophilia, Coagulation, Second Continental Congress, Congress, Plasma, ODA, VII, Patient, Child, Coagulation factor VII, Factor VII deficiency, Growth, Diagnosis, FDA, Treatment, Speciality chemicals, Pharmaceutical industry, Safety, Tisagenlecleucel

The global rare hemophilia factors market is poised for substantial growth, targeting a USD 499.5 million market size by 2030, accompanied by a noteworthy compound annual growth rate (CAGR) of 6.9% from 2023 to 2030.

Key Points: 
  • The global rare hemophilia factors market is poised for substantial growth, targeting a USD 499.5 million market size by 2030, accompanied by a noteworthy compound annual growth rate (CAGR) of 6.9% from 2023 to 2030.
  • The surge in the market is primarily attributed to the increased availability of tailored factor concentrates securing regulatory approvals, notably from the U.S. FDA.
  • Additionally, the rising adoption of prophylaxis treatment among patients is expected to be a significant growth driver in the coming years.
  • Prophylactic treatment is recommended for individuals with severe rare hemophilia factor disorders to prevent bleeding episodes and enhance their quality of life.

H2O Innovation Adds $35.5 M of New O&M and WTS Projects, Showcasing Strong Client Retention and Growth Momentum

Retrieved on: 
Wednesday, September 27, 2023
Other Manufacturing, Engineering, Chemicals, Plastics, Utilities, Manufacturing, Energy, Other Natural Resources, Mining, Minerals, Natural Resources, HEO, Town, NF, Food, Legislation, BNR, Ultrafiltration, NY, Trust, Corporation, City, MBR, Collection, Coagulation, O&M, First Nations, TSX, Operational maintenance, Environment, WTS

“This is a strategic win for us in a region where we already have multiple O&M clients.

Key Points: 
  • “This is a strategic win for us in a region where we already have multiple O&M clients.
  • In addition to the new O&M contracts, H2O Innovation has also renewed four existing contracts across the US.
  • In its WTS business, the Corporation secured five new projects, four of which with existing customers returning to H2O Innovation for additional equipment.
  • The remaining two WTS projects include expansions of existing facilities that were installed by H2O Innovation within the past few years.

Perosphere Technologies Awarded Federal Grants for Point-of-Care Coagulometer

Retrieved on: 
Tuesday, September 19, 2023
General Health, Health, Medical Devices, POC, Pharmacy, SBIR, National Heart, Lung, and Blood Institute, Research, Medical imaging, Lung, ACME, Bangladesh Technical Education Board, NHLBI, Hospital, Physician, Coagulation, National Institute of Biomedical Imaging and Bioengineering, Biological engineering, NIH, Pharmaceutical industry, Medical device

Perosphere Technologies (Perosphere Technologies Inc.), a private medical technologies company focused on developing coagulation diagnostics, has today announced the receipt of two prestigious federal grants: a Direct Phase II Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), and a subaward through an Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) Center Grant, funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB/NIH).

Key Points: 
  • Perosphere Technologies (Perosphere Technologies Inc.), a private medical technologies company focused on developing coagulation diagnostics, has today announced the receipt of two prestigious federal grants: a Direct Phase II Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), and a subaward through an Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) Center Grant, funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB/NIH).
  • The grants, totaling over $2MM, will fund the further development and commercialization of a novel point-of-care (PoC) coagulometer, known as the Perosphere Technologies POC Coagulometer.
  • “We are very honored to receive these grants from NIH and ACME POCT, as they will present a unique opportunity to further expand our groundbreaking point-of-care coagulation diagnostics technology,” said Dr. Stefan Zappe, Principal Investigator and Chief Technology Officer at Perosphere Technologies.
  • “Perosphere Technologies aims to revolutionize coagulation testing by providing healthcare professionals with accurate and timely results.”
    “The potential applications of the Perosphere Technologies PoC Coagulometer will greatly expand thanks to these grant awards, accelerating our understanding of disease mechanisms and therapeutic approaches,” said Dr. Sasha Bakhru, CEO of Perosphere Technologies.

Scientists detail current evidence that Long COVID is caused by persistent SARS-CoV-2 viral reservoirs

Retrieved on: 
Thursday, September 7, 2023
Infection, University, Therapy, COVID-19, SARS-CoV-2, ME/CFS, Biomarker, Multiple sclerosis, Autoimmunity, Harvard Medical School, Patient, UCSF, Coagulation, Nature Immunology, Viral, Paper, PASC, Alzheimer's disease, Pharmaceutical industry, Vaccine, Long COVID

The paper - written by 33 scientists - is titled "SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)."

Key Points: 
  • The paper - written by 33 scientists - is titled "SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)."
  • These reservoirs could be one of the primary drivers of the Long COVID disease process.
  • Importantly, the authors emphasize that antivirals or other drugs should be tested in clinical trials with the goal of clearing SARS-CoV-2 reservoirs in Long COVID patients.
  • Publication of the paper makes it clear that top researchers in the Long COVID space are taking SARS-CoV-2 persistence seriously.

Octapharma's Prothrombin Complex Concentrate, Balfaxar®, Receives FDA Approval For Warfarin Reversal in Urgent Surgery & Invasive Procedures

Retrieved on: 
Wednesday, July 26, 2023
Embolism, Factor IX, Bleeding, Health, Prothrombin time, Factor X, Stroke, Food and Drug Administration, Clinical trial, Thrombophilia, VKA, Octapharma, PCC, INR, Coagulation, Warfarin, Hemostasis, Patient, Protein C, Risk, Physician, Coagulation factor VII, Vitamin K, Trial of the century, Phase, FDA, Thrombin, Food, Safety, Pharmaceutical industry, Medical imaging

Balfaxar® helps restore blood coagulation by replenishing the levels of clotting factors that are deficient due to warfarin therapy.

Key Points: 
  • Balfaxar® helps restore blood coagulation by replenishing the levels of clotting factors that are deficient due to warfarin therapy.
  • The Phase III, randomized, double-blind, multicenter study was performed at 24 sites in the U.S. and Europe and randomized 208 patients to Balfaxar® (N=105) or control 4F-PCC (N=103).
  • We are confident Balfaxar® will be a welcomed treatment for physicians who need to quickly restore patients' coagulation."
  • Balfaxar®, a lyophilized powder for reconstitution, will be provided with sterile water for injection and the new transfer device, nextaro ®.

Reapplix wins 2023 Frost & Sullivan's Best Practices Technology Innovation Leadership Award

Retrieved on: 
Thursday, July 20, 2023
CE, Diabetes, Life, U.S. FDA, Neeraj, Patient, Blood, Coagulation, Centrifuge, Frost, Industry analyst, Pharmaceutical industry

BIRKEROD, Denmark, July 20, 2023 /PRNewswire-PRWeb/ -- Reapplix, a leading company specializing in the biological treatment and management of chronic wounds, today announced it has been awarded a Best Practices Technology Innovation Leadership Award in chronic wound treatment for patients with diabetes by Frost & Sullivan.

Key Points: 
  • BIRKEROD, Denmark, July 20, 2023 /PRNewswire-PRWeb/ -- Reapplix, a leading company specializing in the biological treatment and management of chronic wounds, today announced it has been awarded a Best Practices Technology Innovation Leadership Award in chronic wound treatment for patients with diabetes by Frost & Sullivan.
  • Frost & Sullivan's Technology Innovation Leadership Award recognizes the company that has introduced the best underlying technology for achieving remarkable product and customer success while driving future business value.
  • "We are so honored to receive this recognition from Frost & Sullivan," said Kira Rupprecht, Chief Executive Officer at Reapplix.
  • Each year, Frost & Sullivan applies a rigorous analytical process to evaluate multiple nominees for each award category before determining the final award recipient.

CYBER ENVIRO-TECH, INC PROCURES EXCLUSIVE U.S. LICENSES TO INTELLECTUAL PROPERTY RIGHTS FROM KAM BIOTECHNOLOGY LTD.

Retrieved on: 
Wednesday, July 19, 2023
OTC Markets Group, Partnership, A Total Waste of Makeup, Biotechnology, CETI, Hazardous waste, KAM, Soil, Coagulation, Environment, Fine chemical, Environmental remediation

SCOTTSDALE, Ariz., July 19, 2023 /PRNewswire/ -- (OTC Pink: CETI), Cyber Enviro-Tech, Inc. is pleased to announce the exclusive rights to integrate eight proprietary intellectual biotech compounds from KAM Biotechnology Ltd ("KAM") with CETI's existing systems and processes.

Key Points: 
  • SCOTTSDALE, Ariz., July 19, 2023 /PRNewswire/ -- (OTC Pink: CETI), Cyber Enviro-Tech, Inc. is pleased to announce the exclusive rights to integrate eight proprietary intellectual biotech compounds from KAM Biotechnology Ltd ("KAM") with CETI's existing systems and processes.
  • This will significantly enhance CETI's intricate oil sludge remediation capabilities and contribute to the advancement of its environmentally friendly solutions.
  • KAM's patented products eliminate hazardous chemical interactions in CETI's remediation of soil, sludge, and contaminated water.
  • This allows us to offer a unique Total Waste Solution which is not only ecologically sound but also economically profitable."

Saudi Arabia Water Treatment Chemicals Industry Report 2023-2028 - Focus on Corrosion Inhibitors, Scale Inhibitors, Biocides & Disinfectants, Coagulants & Flocculants, and Chelating Agents

Retrieved on: 
Friday, June 30, 2023
Monterey Peninsula Water Project, Mineral, Petroleum, Coagulation, Climate, CWC, Memory management (operating systems), Flocculation, Rabigh, SWCC, Application, Saline Water Conversion Corporation, Fresh water, Water, Coagulant, Groundwater, ACWA Power, Growth, City, Commercial, Kingdom, Maintenance, Environment, NWC, Natural gas, Oil, Gypsum, Arms industry, Taif, 'Asir Province

To overcome this problem, the treatment of water is necessary; therefore, the demand for water treatment chemicals increases which will increase the market's growth in the upcoming year.

Key Points: 
  • To overcome this problem, the treatment of water is necessary; therefore, the demand for water treatment chemicals increases which will increase the market's growth in the upcoming year.
  • Water treatment is necessary as the demand for clean water increases, which is accomplished using different chemicals and processes.
  • Thus, the coagulant & flocculants type segment is anticipated to grow rapidly in Saudi Arabia Water Treatment Chemicals Market during the forecast period.
  • Company Profiles: Detailed analysis of the major companies in Saudi Arabia Water Treatment Chemicals market.

Hemab Therapeutics Presents New Preclinical Research Demonstrating Effects of Its Bispecific Antibody HMB-001 in Factor VII Deficiency

Retrieved on: 
Saturday, June 24, 2023
Database, Arm, Bleeding, Therapy, Coagulation, Woman, Skull, Coagulopathy, RNA, Doctor of Philosophy, ISTH, Small RNA, Congress, VII, Animal, MD, Thrombosis, International Society on Thrombosis and Haemostasis, European Association of Urology, Phenotype, International Society, Dietary supplement, Glycoprotein IIb/IIIa

COPENHAGEN, Denmark and BOSTON, June 24, 2023 /PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, announced results today from preclinical research of HMB-001 in models of factor VII (FVII) deficiency at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress in Montreal.

Key Points: 
  • "The new preclinical data presented today show HMB-001 successfully targeted and accumulated endogenous FVIIa to levels that would be expected to provide clinical benefit in FVII deficiency, supporting the potential for HMB-001 in an additional underserved bleeding disorder."
  • FVII is a protein necessary in the formation of hemostatic plugs to control bleeding.
  • The total accumulation of FVIIa observed with HMB-001 was comparable to the normal range seen in healthy animals.
  • These initial results suggest HMB-001 may have potential application as a treatment for FVII deficiency.

New Journal of Pharmaceutical Analysis Articles Showcase Innovative Approaches for Diagnostics and Drug Screening and Evaluation

Retrieved on: 
Thursday, June 22, 2023
Elasticity, CVD, Saponin, Panax notoginseng, Workflow, JPA, Cancer, Paclitaxel, Research, PG, RNA, PN, Transcriptome, Patient, Doxorubicin, Coagulation, Immunohistochemistry, Dave's Picks Volume 13, Gene, Breast cancer, Medical imaging, Vaccine

XI'AN, China, June 22, 2023 /PRNewswire/ -- Cancer and cardiovascular diseases (CVDs) continue to be two of the biggest challenges facing modern medicine. Developing better diagnostic procedures, as well as drug screening and assessment techniques, are crucial steps in the path to more effective treatments. The latest issue of the JPA features three articles on cutting-edge research in these directions.

Key Points: 
  • Developing better diagnostic procedures, as well as drug screening and assessment techniques, are crucial steps in the path to more effective treatments.
  • The latest issue of the JPA features three articles on cutting-edge research in these directions.
  • Their findings indicated that saponins found in PG and PN may regulate genes involved in CVD and coagulation, respectively.
  • In the third study , researchers show how the mechanical and physiological properties of a cell can be useful for evaluating drug efficacy.